Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
8 "Pediatrics"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia
Jong Keon Song, Dong Hyeok Lee, Hyery Kim, Sang-Hyun Hwang
Received November 20, 2024  Accepted January 22, 2025  Published online January 24, 2025  
DOI: https://doi.org/10.4143/crt.2024.1114    [Accepted]
AbstractAbstract PDF
Purpose
Acute myeloid leukemia (AML) shows significant heterogeneity in therapeutic responses. We aimed to develop a gene signature for the stratification of high-risk pediatric AML using publicly available AML datasets, with a focus on literature-based prognostic gene sets. Materials and Methods We identified 300 genes from 12 well-validated studies on AML-related gene signatures. Clinical and gene expression data were obtained from three datasets: TCGA-LAML, TARGET-AML, and BeatAML. Least absolute shrinkage and selection operator (LASSO)-Cox regression analysis was used to perform the initial gene selection and to construct a prognostic model using the TCGA database (n=132). The final gene signature was validated with two independent cohorts: BeatAML (n=411) and TARGET-AML (n=187).
Results
We identified a six-gene signature (ETFB, ARL6IP5, PTP4A3, CSK, HS3ST3B1, PLA2G4A), referred to as the literature-based signature 6 (LBS6), that was significantly associated with lower overall survival rates across the TCGA (HR=4.2, 95% CI: 2.59–6.81, p<0.0001), BeatAML (HR=1.52, 95% CI: 1.17–1.96, p=0.0013), and TARGET (HR=2.05, 95% CI: 1.36–3.08, p<0.001) datasets. The high-LBS6 score group exhibited significantly poorer five-year event-free survival compared to the low-LBS6 score group (HR=2.09, 95% CI: 1.38–3.15, p<0.001). After adjusting for key risk factors, including gene mutations (WT1, FLT3, and NPM1), protocol-based risk group, WBC count, and age, the LBS6 score was independently associated with worse survival rates in validation cohorts.
Conclusion
Our literature-driven approach identified a robust gene signature that stratifies AML patients into distinct risk groups. The LBS6 score shows promise in redefining initial risk stratification and identifying high-risk AML patients.
  • 278 View
  • 31 Download
Close layer
Survival of Children with Acute Lymphoblastic Leukemia with Risk Group–Based Protocol Changes: A Single-Center Experience with 460 Patients over a 20-Year Period
Na Hee Lee, Hee Young Ju, Eun Sang Yi, Young Bae Choi, Keon Hee Yoo, Hong Hoe Koo
Received February 6, 2024  Accepted September 21, 2024  Published online September 27, 2024  
DOI: https://doi.org/10.4143/crt.2024.127    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent treatments for pediatric acute lymphoblastic leukemia (ALL) are founded on risk stratification. We examined the survival rates and prognostic factors of patients over a 20-year period at a single institution.
Materials and Methods
This study analyzed patients diagnosed with ALL and treated at the Pediatric Department of Samsung Medical Center (SMC). Patients were categorized into standard-risk (SR), high-risk (HR), and very high-risk (VHR) groups. The SMC protocol for the HR group underwent two changes during the study period: a modified Children’s Cancer Group (CCG)-1882 protocol was used from 2000 to 2005, the Korean multicenter HR ALL-0601 protocol from 2006 to 2014, and the Korean multicenter HR ALL-1501 protocol from 2015 to 2019.
Results
Of the 460 patients, complete remission was achieved in 436 patients (94.8%). The 10-year overall survival rate (OS) was 83.8±1.9% for all patients. OS according to the SMC risk group was as follows: 95.9%±1.4% in the SR group, 83.8%±3.6% in the HR group, and 66.2%±6.9% in the VHR group. The 5-year OS within the HR group varied according to the treatment protocol: 73.9%±7.5%, in the modified CCG-1882 protocol, 83.0%±3.9%, in the 0601 protocol, and 96.2%±2.6%, in the 1501 protocol. For those aged 15 years and older, the OS was only 56.5%±13.1%. Relapse occurred in 71 patients (15.4%), and the OS after relapse was 37.7%±6.0%.
Conclusion
The treatment outcomes of patients with ALL improved markedly. However, there is a need to further characterize adolescents and young adult patients, as well as those who have experienced relapses.
  • 418 View
  • 39 Download
Close layer
Pediatric cancer
Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) System for Pediatric Patients with Hepatoblastoma: A Retrospective, Hospital-Based Cohort Study in South Korea
Pyeong Hwa Kim, Hyun Joo Shin, Hee Mang Yoon, Young Hun Choi, Jung-Man Namgoong, Dae Yeon Kim, Kyung-Nam Koh, Mi-Jung Lee, Haesung Yoon, Chuhl Joo Lyu, Jung Woo Han, Seung Min Hahn, Young Ah Cho
Cancer Res Treat. 2022;54(1):253-258.   Published online March 24, 2021
DOI: https://doi.org/10.4143/crt.2021.265
AbstractAbstract PDFPubReaderePub
Purpose
In 2017, the Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system was introduced. We aimed to evaluate the accuracy of CHIC-HS System for the prediction of event-free survival (EFS) in Korean pediatric patients with hepatoblastoma.
Materials and Methods
This two-center retrospective study included consecutive Korean pediatric patients with histopathologically confirmed hepatoblastoma from March 1988 through September 2019. We compared EFS among four risk groups according to the CHIC-HS system. Discriminatory ability of CHIC-HS system was also evaluated using optimism-corrected C-statistics. Factors associated with EFS were explored using multivariable Cox regression analysis.
Results
We included 129 patients (mean age, 2.6±3.3 years; female:male, 63:66). The 5-year EFS rates in the very low, low, intermediate, and high-risk groups, according to the CHIC-HS system were 90.0%, 82.8%, 73.5%, and 51.3%, respectively. The CHIC-HS system aligned significantly well with EFS outcomes (p=0.004). The optimism-corrected C index of CHIC-HS was 0.644 (95% confidence interval [CI], 0.561 to 0.727). Age ≥ 8 (vs. age ≤ 2; hazard ratio [HR], 2.781; 95% CI, 1.187 to 6.512; p=0.018), PRE-Treatment EXTent of tumor (PRETEXT) stage IV (vs. PRETEXT I or II; HR, 2.774; 95% CI, 1.228 to 5.974; p=0.009), and presence of metastasis (HR, 2.886; 95% CI, 1.457 to 5.719; p=0.002), which are incorporated as the first three nodes in the CHIC-HS system, were independently associated with EFS.
Conclusion
The CHIC-HS system aligned significantly well with EFS outcomes in Korean pediatric patients with hepatoblastoma. Age group, PRETEXT stage, and presence of metastasis were independently associated with EFS.

Citations

Citations to this article as recorded by  
  • Elevated serum uric acid is associated with the risk of advanced staging and vascular involvement in patients with hepatoblastoma: a 14-year retrospective study
    Yunlan Zhou, Jinning Li, Yanhui Ma, Mengjie Tang, Xiaojun Yuan, Lisong Shen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • 6,245 View
  • 211 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Case Report
Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
Marco Focaccia, Marco Gambarotti, Rossella Hakim, Anna Paioli, Marilena Cesari, Benedetta Spazzoli, Paolo Spinnato, Davide Donati, Michele Rocca, Alessandra Longhi
Cancer Res Treat. 2021;53(1):279-282.   Published online August 6, 2020
DOI: https://doi.org/10.4143/crt.2020.384
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Chondroblastoma is a rare benign chondrogenic tumor that occurs in skeletally immature patients between ages 10 and 20 years old. In literature are reported few cases of lung metastases, mainly occurred after surgery or local recurrences. There is no evidence on the pathogenesis of lung metastasis, as well as pulmonary disease course. Few treatments for metastases with aggressive behavior were based on chemotherapy regimen employed in other sarcoma with no results or not satisfying ones. Denosumab is approved for treatment of giant cell tumors and it is under investigation for other giant cell-rich bone tumors. Here, we report a case of a 16-year-old male chondroblastoma of the left humerus with bilateral lung metastases at presentation and progressing during follow-up, treated with denosumab for almost 2 years. We confirm that denosumab treatment can be effective in controlling chondroblastoma metastasis and it has been a safe procedure in an adolescent patient.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and outcomes of patients with chondroblastoma undergoing surgery with various adjuvant procedures: a retrospective study of 59 cases
    Toru Hirozane, Tetsuya Sekita, Eisuke Kobayashi, Tomoaki Mori, Naofumi Asano, Toru Udaka, Takashi Tajima, Rumi Nakagawa, Kazutaka Kikuta, Akira Yoshiyama, Hideo Morioka, Itsuo Watanabe, Ukei Anazawa, Michiro Susa, Keisuke Horiuchi, Yoshihisa Suzuki, Takes
    BMC Surgery.2025;[Epub]     CrossRef
  • 3D Specimen Scanning and Mapping in Musculoskeletal Oncology: A Feasibility Study
    Juan M. Colazo, Kavita Prasad, Alexis Miller, Kayvon Sharif, Marina Aweeda, Carly Fassler, Reena Singh, Herbert S. Schwartz, Joshua M. Lawrenz, Ginger E. Holt, Michael C. Topf
    Annals of Surgical Oncology.2024; 31(3): 2051.     CrossRef
  • Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches
    Ramy Samargandi, Abrar Bafail, Louis-Romée Le Nail, Julien Berhouet
    Cancers.2024; 16(12): 2283.     CrossRef
  • Chondroblastoma Affecting the Apophysis of the Greater Trochanter in a Child
    Svetoslav A Slavchev, Philip J O'Connor, Georgi P Georgiev
    Cureus.2023;[Epub]     CrossRef
  • Recurrent chondroblastoma of the talus: A case report and literature review of recurrent lesions in the foot and ankle
    Olivia Jagiella-Lodise, Timothy McAleese, Mark Curtin, Alan Molloy, James Walsh
    International Journal of Surgery Case Reports.2023; 106: 108192.     CrossRef
  • Huge Chondroblastoma of the Talus: A Case Report
    Sung Hyun Yoon, Hyun-woo Park
    Journal of Korean Foot and Ankle Society.2023; 27(4): 154.     CrossRef
  • A Rare Case of Chondroblastoma from Neolithic Crete of the 7th Millennium BCE
    Anagnostis P. Agelarakis, Lisa M. DiFrancesco, Lukas Delasos, Julian Samodulski, Athanasia Kanta, Panayotis G. Agelarakis
    Paléorient.2023; (49-1): 229.     CrossRef
  • Pulmonary Metastases of Chondroblastoma in a Pediatric Patient: A Case Report and Review of Literature
    Courtney Wing, Pankaj Watal, Monica Epelman, Juan Infante, Tushar Chandra
    Cureus.2022;[Epub]     CrossRef
  • 5,938 View
  • 131 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Original Articles
Pediatric Adenocarcinoma in Korea: A Multicenter Study
Hee-Beom Yang, Jung-Man Namgoong, Ki Hoon Kim, Dae Yeon Kim, Jinyoung Park, Hyun Beak Shin, Joong Kee Youn, Sanghoon Lee, Ji Won Lee, Sung Eun Jung, Jae Hee Chung, Yun-Mee Choe, Tae Gil Heo, In Geol Ho, Hyun-Young Kim
Cancer Res Treat. 2020;52(1):117-127.   Published online June 3, 2019
DOI: https://doi.org/10.4143/crt.2019.092
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Adenocarcinoma is an extremely rare malignancy in the pediatric population. Research regarding pediatric adenocarcinoma is very rare in Korea. This study aimed to investigate the clinical features of pediatric adenocarcinomas of various primary organ sites in Korea.
Materials and Methods
Pediatric patients under 18 years, diagnosed with adenocarcinoma of various sites between January 1995 and December 2016, were included. We retrospectively reviewed patient and tumor characteristics and calculated survival estimates, reported as 5-year survival rate and 95% confidence interval.
Results
Of 80 patients (median age, 15 years; range, 10 to 17 years), 37 (46.3%) were men, and 24 (30%) had a family history of cancer or underlying disease relevant to malignancy. The cancer locations were the colon and rectum (n=32), ovaries (n=18), stomach (n=15), lung (n=4), small bowel (n=1), and other sites (n=10). Totally, 54.8% patients (42/77) had stage 3 or 4 disease. The median follow-up period was 2.0 years (range, 0 to 20.4). The 5-year overall survival estimate for all patients, and for those with stomach, colorectal, ovarian, and other cancer sites were 57.9%±11.5%, 58.2%±25.7%, 41.5%±18.2%, 87.5%±16.2%, and 64.0%±34.4%, respectively. The 5-year survival rate differed significantly between categories of adenocarcinomas into gastrointestinal (GI) (44.7%) and non-GI adenocarcinomas (78.8%) (p=0.007). The 5-year survival rate also differed significantly according to carcinoembryonic antigen level (69.3% in < 3 ng/mL, 23.8% in > 3 ng/mL; p < 0.001).
Conclusion
In pediatric patients, adenocarcinomas arise from various organs and are often diagnosed at advanced stages. Large, prospective studies for their accurate clinical characteristics and prognostic factors are needed.

Citations

Citations to this article as recorded by  
  • Nomogram to predict central lymph node metastasis in papillary thyroid carcinoma
    Dehui Qiao, Xian Deng, Ruichen Liang, Xu Li, Rongjia Zhang, Zhi Lei, Hui Yang, Xiangyu Zhou
    Clinical & Experimental Metastasis.2024; 41(5): 613.     CrossRef
  • Artificial intelligence–based prediction of cervical lymph node metastasis in papillary thyroid cancer with CT
    Cai Wang, Pengyi Yu, Haicheng Zhang, Xiao Han, Zheying Song, Guibin Zheng, Guangkuo Wang, Haitao Zheng, Ning Mao, Xicheng Song
    European Radiology.2023; 33(10): 6828.     CrossRef
  • Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas
    Luisella Righi, Alberto Righi, Simona Vatrano, Ida Rapa, Angela Listì, Jasna Metovic, Michele Rocca, Mariacristina Salone, Paolo Giovenali, Angelo Sidoni, Fabrizio Tabbò, Angelo Paolo Dei Tos, Marco Volante, Mauro Papotti
    Virchows Archiv.2021; 478(6): 1125.     CrossRef
  • Case Report: Primary Bilateral Minimally Invasive Adenocarcinoma of the Lungs in an 11-Year-Old Child: A Rare Case
    Xing Lei, Yongfei Zheng, Guohua Zhang, Hailan Zheng
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • 8,714 View
  • 244 Download
  • 2 Web of Science
  • 4 Crossref
Close layer
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
Hyery Kim, Heewon Seo, Yoomi Park, Byung-Joo Min, Myung-Eui Seo, Kyung Duk Park, Hee Young Shin, Ju Han Kim, Hyoung Jin Kang
Cancer Res Treat. 2018;50(3):823-834.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients.
Materials and Methods
Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients.
Results
Using bioinformatics tools and genetic data, four functionally interesting variants were selected (ABCC4, APEX1, CYP1A1, and CYP4F2). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in APEX1 rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with APEX1 rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01).
Conclusion
We have identified that APEX1 rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. APEX1 and NUDT15 both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.

Citations

Citations to this article as recorded by  
  • Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response
    Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali, Uppugunduri S. Chakradhara Rao
    Pharmaceuticals.2022; 15(8): 990.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT
    Hyery Kim, Seungwon You, Yoomi Park, Jung Yoon Choi, Youngeun Ma, Kyung Tak Hong, Kyung-Nam Koh, Sunmin Yun, Kye Hwa Lee, Hee Young Shin, Suehyun Lee, Keon Hee Yoo, Ho Joon Im, Hyoung Jin Kang, Ju Han Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives
    Gabriela Betlej, Ewelina Bator, Antoni Pyrkosz, Aleksandra Kwiatkowska
    Genes.2020; 11(6): 643.     CrossRef
  • Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT
    Yoomi Park, Hyery Kim, Heewon Seo, Jung Yoon Choi, Youngeun Ma, Sunmin Yun, Byung-Joo Min, Myung-Eui Seo, Keon Hee Yoo, Hyoung Jin Kang, Ho Joon Im, Ju Han Kim
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology
    Emma C. Bernsen, Melanie M. Hagleitner, Theodorus W. Kouwenberg, Lidwien M. Hanff
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis
    Ho Jung Choi, Juhee Shin, Sunghan Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
    BLOOD RESEARCH.2020; 55(4): 262.     CrossRef
  • NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
    Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
    Cancer Research and Treatment.2018; 50(3): 872.     CrossRef
  • 23,953 View
  • 333 Download
  • 12 Web of Science
  • 9 Crossref
Close layer
Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience
Dong Hwan Kim, Seung Yeon Kim, Hyeon Jeong Lee, Bong Sup Song, Dong Ho Kim, Joong Bum Cho, Jung Sub Lim, Jun Ah Lee
Cancer Res Treat. 2011;43(3):170-175.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.170
AbstractAbstract PDFPubReaderePub
PURPOSE
Response to neo-adjuvant chemotherapy is an important prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). [F-18]-fluorodeoxy-D-glucose (FDG)-positron emission tomography (PET) is a non-invasive imaging modality that predicts histologic response to chemotherapy of various malignancies; however, limited data exist about the usefulness of FDG-PET in predicting the histologic response of pediatric bone tumors to chemotherapy. We analyzed the FDG-PET imaging characteristics of pediatric bone tumors and determined the association with response to chemotherapy.
MATERIALS AND METHODS
Pediatric patients with OS (n=19) or ESFT (n=17) were evaluated for FDG-PET standard uptake values before (SUV1) and after (SUV2) chemotherapy. The relationship to the chemotherapy response was assessed by histopathology in surgically-excised tumors. A complete data set (SUV1, SUV2, and histologic response) was available in 23 patients.
RESULTS
While the mean SUV1s were not different between patients with OSs and ESFTs (9.44 vs. 6.07, p=0.24), the SUV2s were greater in the patients with OSs than ESFTs (4.55 vs. 1.66, p=0.01). The ratios of SUV2-to-SUV1 (SUV2 : SUV1) were 0.65 and 0.35 for OS and ESFT, respectively (p=0.08). All of the patients with ESFTs and 47% of the patients with OS had a favorable histologic response to chemotherapy. The SUV2 : 1 [(SUV1-SUV2)/SUV1]> or =0.5 and SUV2< or =2.5 were related to favorable histologic responses to chemotherapy; the sensitivity and specificity of SUV2 : 1 at 0.5 and SUV2 at 2.5 were 93% and 88%, and 88% and 78%, respectively.
CONCLUSION
FDG-PET can be used as a non-invasive surrogate to predict response to chemotherapy in children with bone tumors.

Citations

Citations to this article as recorded by  
  • 18F-FDG PET/CT in the Management of Osteosarcoma
    Chiwoo Oh, Michael W. Bishop, Steve Y. Cho, Hyung-Jun Im, Barry L. Shulkin
    Journal of Nuclear Medicine.2023; 64(6): 842.     CrossRef
  • [18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma
    Alessio Annovazzi, Virginia Ferraresi, Vincenzo Anelli, Renato Covello, Sabrina Vari, Carmine Zoccali, Roberto Biagini, Rosa Sciuto
    European Radiology.2021; 31(9): 7012.     CrossRef
  • Different 18F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors
    Gihan El‐Hennawy, Hosna Moustafa, Walid Omar, Naglaa Elkinaai, Ahmad Kamel, Iman Zaki, Nesma Farid, Esraa El‐Kholy
    Pediatric Blood & Cancer.2020;[Epub]     CrossRef
  • Sarcomes osseux
    J.L. Albérini, P.Y. Salaün
    Médecine Nucléaire.2019; 43(1): 138.     CrossRef
  • Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma
    Antonio Ruggiero, Valerio Lanni, Alberto Librizzi, Palma Maurizi, Giorgio Attinà, Stefano Mastrangelo, Alessandro Giordano, Riccardo Riccardi
    Journal of Pediatric Hematology/Oncology.2018; 40(4): 277.     CrossRef
  • The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence
    Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri
    European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(10): 1712.     CrossRef
  • PET/CT of Osteosarcoma and Ewing Sarcoma
    Colleen M. Costelloe, Hubert H. Chuang, Najat C. Daw
    Seminars in Roentgenology.2017; 52(4): 255.     CrossRef
  • Qualitative and Semi-Quantitative 18-F FDG PET/CT for Osteosarcoma: A Review
    Lorenzo Nardo, Michelle Zhang, Luca Facchetti, Benjamin L. Franc
    Current Radiology Reports.2017;[Epub]     CrossRef
  • Tumour hypoxia: lessons learnt from preclinical imaging
    Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Clinical and Translational Imaging.2017; 5(5): 407.     CrossRef
  • Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging
    Natale Quartuccio, Byung Hyun Byun, Pierpaolo Alongi, Federico Caobelli, Chang-Bae Kong, Sang Moo Lim, Angelina Cistaro
    Clinical and Translational Imaging.2016; 4(1): 41.     CrossRef
  • Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
    G. N. Machak, A. K. Morozov, A. I. Snetkov, I. N. Karpov, N. V. Kochergina, A. B. Bludov, A. D. Ryzhkov
    Vestnik travmatologii i ortopedii imeni N.N. Priorova.2016; (3): 53.     CrossRef
  • Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
    G. N Machak, A. K Morozov, A. I Snetkov, I. N Karpov, N. V Kochergina, A. B Bludov, A. D Ryzhkov
    N.N. Priorov Journal of Traumatology and Orthopedics.2016; 23(3): 53.     CrossRef
  • Radiotherapy and gemcitabine–docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma
    Jun Ah Lee, Eun Kyung Paik, Juhee Seo, Dong Ho Kim, Jung Sub Lim, Ji Young Yoo, Mi-Sook Kim
    Japanese Journal of Clinical Oncology.2015; : hyv171.     CrossRef
  • Tumor‐to‐background Ratio to Predict Response to Chemotherapy of Osteosarcoma Better than Standard Uptake Values
    Jin‐peng He, Yun Hao, Mi Li, Jiang Wang, Feng‐jin Guo
    Orthopaedic Surgery.2014; 6(2): 145.     CrossRef
  • Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
    Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Otto C. Boerman, Winette T.A. van der Graaf
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1845(2): 266.     CrossRef
  • FDG PET/CT of Primary Bone Tumors
    Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell
    American Journal of Roentgenology.2014; 202(6): W521.     CrossRef
  • Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET
    Zachary Sanford, Stanford Israelsen, Rajesh Sehgal, Felix H. Cheung
    Skeletal Radiology.2014; 43(6): 819.     CrossRef
  • Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models
    Carmen Campanile, Matthias J.E. Arlt, Stefanie D. Krämer, Michael Honer, Ana Gvozdenovic, Patrick Brennecke, Cindy R. Fischer, Adam A. Sabile, Adrienne Müller, Simon M. Ametamey, Walter Born, Roger Schibli, Bruno Fuchs
    Journal of Nuclear Medicine.2013; 54(8): 1362.     CrossRef
  • Promise and pitfalls of quantitative imaging in oncology clinical trials
    Brenda F. Kurland, Elizabeth R. Gerstner, James M. Mountz, Lawrence H. Schwartz, Christopher W. Ryan, Michael M. Graham, John M. Buatti, Fiona M. Fennessy, Edward A. Eikman, Virendra Kumar, Kenneth M. Forster, Richard L. Wahl, Frank S. Lieberman
    Magnetic Resonance Imaging.2012; 30(9): 1301.     CrossRef
  • 18F NaF PET/CT in the Assessment of Malignant Bone Disease
    Camila Mosci, Andrei Iagaru
    PET Clinics.2012; 7(3): 263.     CrossRef
  • The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma
    Carmelo Caldarella, Marco Salsano, Maria Antonietta Isgrò, Giorgio Treglia
    International Journal of Molecular Imaging.2012; 2012: 1.     CrossRef
  • 12,548 View
  • 73 Download
  • 21 Crossref
Close layer
Clinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation
Ji Won Lee, Hyery Kim, Hyoung Jin Kang, Han-Soo Kim, Sung-Hye Park, In-One Kim, Hyo Seop Ahn, Hee Young Shin
Cancer Res Treat. 2008;40(4):172-177.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.172
AbstractAbstract PDFPubReaderePub
Purpose

In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).

Materials and Methods

We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.

Results

The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.

Conclusions

The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.

Citations

Citations to this article as recorded by  
  • High‐dose chemotherapy followed by autologous stem cell transplantation in pediatric patients with relapsed osteosarcoma
    Sung Han Kang, Wanlim Kim, Jong Seok Lee, Jin Kyung Suh, Hyery Kim, Dong Kwan Kim, Se Hoon Choi, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Sung Wook Seo, Ho Joon Im, Ji Won Lee, Kyung‐Nam Koh
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis
    Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Jung-Eun Cheon, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
    Mohammadreza Bordbar, Ali Sarfaraz, Sezaneh Haghpanah, Omidreza Zekavat, Soheila Zareifar, Tahereh Zarei
    Global Pediatric Health.2021;[Epub]     CrossRef
  • 1
    L.V. Hryvkova
    Practical oncology.2021; 4(1): 30.     CrossRef
  • Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma
    Suguru Uemura, Takeshi Mori, Shinya Ishiko, Satoru Takafuji, Nanako Nino, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Hitomi Hara, Teruya Kawamoto, Toshihiro Akisue, Kazumoto Iijima
    Pediatric Hematology and Oncology.2020; 37(4): 337.     CrossRef
  • Pulmonary tuberculosis mimicking radiation pneumonitis in a patient with neck malignancy
    Kyungsoo Bae, Kyung Nyeo Jeon, Hoon Sik Choi, Dae Hyun Song, Ho Cheol Kim
    Medicine.2019; 98(27): e16398.     CrossRef
  • High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
    C R Hong, H J Kang, M S Kim, H Y Ju, J W Lee, H Kim, H-S Kim, S-H Park, K D Park, J D Park, H Y Shin, H S Ahn
    Bone Marrow Transplantation.2015; 50(10): 1375.     CrossRef
  • High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study
    Kjetil Boye, Adalberto Brach Del Prever, Mikael Eriksson, Gunnar Sæter, Amelia Tienghi, Paula Lindholm, Franca Fagioli, Sigmund Skjeldal, Stefano Ferrari, Kirsten Sundby Hall
    Pediatric Blood & Cancer.2014; 61(5): 840.     CrossRef
  • LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy
    XIN HUA LONG, ZHEN HAO ZHONG, AI FEN PENG, LIANG BO ZHU, HENG WANG, GUO MEI ZHANG, ZHI LI LIU
    Molecular Medicine Reports.2014; 10(6): 2967.     CrossRef
  • Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
    Colin Moore, Don Eslin, Alejandro Levy, Jessica Roberson, Vincent Giusti, Robert Sutphin
    Pediatric Blood & Cancer.2010; 55(6): 1096.     CrossRef
  • Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma
    Masanori Kawano, Hideji Nishida, Yasunari Nakamoto, Hiroshi Tsumura, Hiroyuki Tsuchiya
    Clinical Orthopaedics and Related Research®.2010; 468(5): 1373.     CrossRef
  • 10,305 View
  • 67 Download
  • 11 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP